GS-1101 (CAL-101) – idelalisib
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GS-1101 (CAL-101) – idelalisib, covering 2012-09-07 to 2012-09-07. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia [Phase 2]